Compare ROIV & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROIV | RGEN |
|---|---|---|
| Founded | 2014 | 1981 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 8.2B |
| IPO Year | N/A | N/A |
| Metric | ROIV | RGEN |
|---|---|---|
| Price | $21.70 | $164.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $24.31 | ★ $174.90 |
| AVG Volume (30 Days) | ★ 8.2M | 583.5K |
| Earning Date | 02-09-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $20,329,000.00 | ★ $707,890,000.00 |
| Revenue This Year | N/A | $17.84 |
| Revenue Next Year | $741.42 | $12.44 |
| P/E Ratio | ★ N/A | $6,546.81 |
| Revenue Growth | N/A | ★ 11.74 |
| 52 Week Low | $8.73 | $102.97 |
| 52 Week High | $23.47 | $182.52 |
| Indicator | ROIV | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.94 | 55.35 |
| Support Level | $21.36 | $161.41 |
| Resistance Level | $22.72 | $167.65 |
| Average True Range (ATR) | 0.80 | 4.45 |
| MACD | -0.13 | 0.06 |
| Stochastic Oscillator | 45.25 | 75.36 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.